NCT07931573: AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
- State
- Not started
- Phase
- Phase 3
- People
- 1,200 planned
- Started
- 10 Nov 2026
- Primary completion
- 4 Jul 2028
- Arms
- Zenagamtide
- Results
- None posted
- 12 Nov 2026: Trial registered